Related Experiment Video
Updated: Nov 2, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
3.0K
COVID-19: Where is the treatment?
Bonala Sabeerabi1, Sarojamma Vemula2, Ramakrishna Vadde3
1Department of Biochemistry, Biostandups, Hyderabad 500039, Telangana, India.
World Journal of Clinical Oncology
|June 16, 2021
Summary
This review found that common therapies like anti-viral and immune treatments offer no clinical benefit for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients and may cause adverse effects.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health challenge, necessitating effective treatments.
- Existing therapeutic strategies for SARS-CoV-2 are still under investigation, despite its relation to SARS-CoV and MERS-CoV.
Purpose of the Study:
- To systematically review and meta-analyze the clinical efficacy and safety of various therapeutic strategies for SARS-CoV-2.
- To evaluate the benefits of anti-viral, anti-malaria, immune, and hormone therapies in managing coronavirus disease 2019 (COVID-19).
Main Methods:
- Conducted a systematic review and meta-analysis of existing studies on SARS-CoV-2 therapeutics.
- Synthesized evidence from clinical trials assessing the impact of various treatment categories on COVID-19 patient outcomes.
Main Results:
- The analyzed therapeutic strategies, including anti-viral and immune-based treatments, demonstrated no significant clinical benefits for COVID-19 patients.
- These therapies were associated with adverse side effects, indicating potential harm.
Conclusions:
- Current therapeutic approaches explored for SARS-CoV-2 lack proven clinical efficacy and may present safety concerns.
- Further research is crucial to identify safe and effective treatments for coronavirus disease 2019.
Related Concept Videos
01:28Pneumonia IV: Management
534
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
534
01:29Acute Respiratory Failure-V
254
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
254
01:28Pulmonary Tuberculosis V
286
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
286
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:26Tonsillitis II: Management
230
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
230
01:14Myocarditis III: Medical Management
43
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
43